scholarly journals Comparison of 11C-L-methionine uptake by the parotid gland and pancreas in chronic pancreatitis studied by positron emission tomography.

Gut ◽  
1983 ◽  
Vol 24 (7) ◽  
pp. 637-641 ◽  
Author(s):  
A Syrota ◽  
P Collard ◽  
A Paraf
1989 ◽  
Vol 30 (2) ◽  
pp. 121-128 ◽  
Author(s):  
A. Lilja ◽  
H. Lundqvist ◽  
Y. Olsson ◽  
B. Spännare ◽  
P. Gullberg ◽  
...  

In previous studies of supratentorial gliomas with positron emission tomography (PET) and computed tomography (CT), high uptakes of L-methyl-11C-methionine (11C-L-methionine) were found even in astrocytomas without blood-brain barrier defects as judged by CT or 68Ga-EDTA PET. In a number of patients examined after radiation therapy, there were no consistent changes in the high uptake values. In the present investigation PET and CT were compared with regard to their abilities to visualize and delineate recurrent tumors and treatment-induced brain defects and to differentiate between them. The study was undertaken on four patients who were long-term survivors after treatment for high-grade gliomas. For PET, 11C-L-methionine and 68Ga-EDTA were used. In two patients recurrent/residual tumors appeared considerably larger with 11C-L-methionine PET than with CT or 68Ga-EDTA PET. In one patient, no signs of recurrence were seen with any of these three methods, and in a fourth patient, whose condition was clinically stable, the findings at PET with 11C-L-methionine were non-specific. In areas corresponding to the surgical parenchymal defects, the 11C-L-methionine uptake and, except in one case, the local blood volume was markedly reduced. PET with 11C-L-methionine thus has a potential for distinguishing between postoperative brain lesions and tumor recurrence with a higher accuracy than CT.


2006 ◽  
Vol 134 (4) ◽  
pp. 708-709 ◽  
Author(s):  
Kouji Hagino ◽  
Atsunobu Tsunoda ◽  
Akiko Ishihara ◽  
Seiji Kishimoto ◽  
Takayuki Suzuki ◽  
...  

2019 ◽  
Vol 1 (Supplement_2) ◽  
pp. ii25-ii26
Author(s):  
Yoshiko Okita ◽  
Tomoko Shofuda ◽  
Daisuek Kanematsu ◽  
Ema Yoshioka ◽  
Yoshinori Kodama ◽  
...  

Abstract AIM We evaluated the association between 11C-methionine positron emission tomography (11C-methionine PET) findings, isocitrate dehydrogenase (IDH) gene mutation, and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in patients with grade II and III gliomas. MATERIALS AND METHODS Data were collected from 40 patients with grade II and III gliomas who underwent both magnetic resonance imaging (MRI) and 11C-methionine positron emission tomography (PET) as part of their pre-surgical examination. We examined IDH mutation through DNA sequencing, and MGMT promoter methylation through quantitative methylation-specific polymerase chain reaction (PCR). RESULTS A threshold of MGMT promoter methylation of 1.0% was significantly associated with tumor/normal tissue (T/N) ratio. The T/N ratio in samples with MGMT promoter methylation ≥1.0% was higher than that in samples with MGMT promoter methylation <1.0%, and the difference was statistically significant (p = 0.011). Reliable prediction of MGMT promoter methylation (<1.0% vs ≥1.0%) was possible using the T/N ratio under the receiver operator characteristic (ROC) curve with a sensitivity and specificity of 75% each (cut-off value = 1.6) (p = 0.0226, AUC = 0.76172). Conversely, the T/N ratio had no association with IDH mutation (p = 0.6). The ROC curve revealed no reliable prediction of IDH mutation using the T/N ratio (p = 0.606, AUC = 0.60577). CONCLUSION 11C-methionine PET parameters can predict MGMT promoter methylation but not IDH mutation status. 11C-methionine uptake may have limited potential to reflect DNA methylation processes in grade II and III gliomas.


Sign in / Sign up

Export Citation Format

Share Document